NCT07489651

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (estimated)
• Sponsor: Reunion Neuroscience Inc · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	RE104 for Injection	Single, subcutaneous dose of RE104 for Injection
DRUG	Placebo	Single, subcutaneous dose of 0.9% sodium chloride for injection

Timeline

• Start date: 2026-04-01
• Primary completion: 2027-02-01
• Completion: 2027-04-01
• First posted: 2026-03-24
• Last updated: 2026-03-24

Regulatory

• FDA-regulated drug study